Boehringer Ingelheim Launches SGLT-2 Inhibitor Diabetes Treatment 'Dapagliflozin'

Bioson Pharmaceutical announced on the 11th the launch of 'Daparozin Tab,' a diabetes treatment containing dapagliflozin, a sodium-glucose co-transporter (SGLT)-2 inhibitor, and 'Daparozin Duo Extended-Release Tab (10/1000 mg),' a combination with metformin.

Vivozon Pharmaceutical's SGLT-2 inhibitor class diabetes treatment 'Dapagliflozin'
[Photo by Vivozon Pharmaceutical]

Daparozin Tab and Daparozin Duo Extended-Release Tab lower blood sugar by inhibiting glucose reabsorption in the kidneys of patients with type 2 diabetes, and also have effects of lowering blood pressure and reducing body weight. According to diabetes treatment guidelines, the use of SGLT-2 inhibitors is primarily recommended for diabetic patients with complications such as heart failure, atherosclerosis, and chronic kidney disease.

In particular, Daparozin Tab and Daparozin Duo Extended-Release Tab lower blood sugar independently of insulin action, resulting in minimal side effects such as hypoglycemia and weight gain. Daparozin Tab can be taken once daily regardless of meals, greatly improving medication convenience for diabetic patients.

A representative from Bioson Pharmaceutical stated, “Daparozin Tab and Daparozin Duo Extended-Release Tab, SGLT-2 inhibitor class diabetes treatments, have proven efficacy and safety through large-scale clinical trials and extensive clinical experience. Especially, the dapagliflozin component offers broader conditions for combination prescriptions in dual therapy compared to other SGLT-2 inhibitor class components, which is expected to provide various treatment options for diabetic patients.”

This content was produced with the assistance of AI translation services.